Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Flapless Application of Enamel Matrix Derivative in Class II Mandibular Furcation Defects: a Randomized Clinical Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05541614
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:17.279725+00:00
Published At
2023-03-07T00:00:00+00:00
Record Updated At
2023-03-07
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Periodontal Diseases", "Periodontal Disease, AVDC Stage 3", "Periodontal Disease, AVDC Stage 4", "Furcation Defects"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-03-07"
protocolSection.identificationModule.nctId
"NCT05541614"
protocolSection.identificationModule.officialTitle
"Flapless Application of Enamel Matrix Derivative in Class II Mandibular Furcation Defects: a Randomized Clinical Trial"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Periodontal Diseases (protocolSection.conditionsModule.conditions)
  • Periodontal Disease, AVDC Stage 3 (protocolSection.conditionsModule.conditions)
  • Periodontal Disease, AVDC Stage 4 (protocolSection.conditionsModule.conditions)
  • Furcation Defects (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.